Transgene S.A. Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest, by Hedi Ben Brahim, was filed 13 Sept 2023.
Transgene S.A.: what insiders have been doing
This page follows insider dealings at Transgene S.A. as filed with AMF, a company from the Healthcare & Pharma sector. The last twelve months, up to 10 November 2026, brought 1 filing signed by 1 insider.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Over the last twelve months, not one insider purchase of Transgene S.A. stock was filed.
For context, the typical company on the same exchange (median of 316 companies) published 6 filings over the same period, against 1 filing here. The full history, which starts in 2021, counts 2 purchases against no sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from AMF. Past trades are no guide to future returns.
Financial data
as of FY 2025FY ended December 2025 · cache
- 123,237,572 shares@ €1.02100.0% of flowActionEuronext ParisISIN FR00051750802025DD1071974
- 30,898,876 shares@ €1.06856.9% of flowActionEuronext ParisISIN FR00051750802024DD989520
- 114,284 shares0ActionEuronext ParisISIN FR00051750802023DD927465Canonical exit: 24 Aug 2023 (T+90)
- 29,325 shares0ActionEuronext ParisISIN FR00051750802023DD912457Canonical exit: 24 Aug 2023 (T+90)
- 10,204,000 shares@ €2.4543.1% of flowActionEuronext ParisISIN FR00051750802021DD761171
5 of 5 declarations
About Transgene S.A.
Transgene S.A. is a French biotechnology company listed on Euronext Paris under ticker TNG and ISIN FR0005175080. Headquartered in Strasbourg since its creation, the company designs and develops innovative cancer immunotherapies, with a strong focus on viral-vector-based approaches and individualized therapeutic vaccines. Founded in December 1979, Transgene is part of France’s long tradition in genetic engineering and remains a research-stage biopharmaceutical company, still pre-commercial, whose value creation depends on clinical proof-of-concept, platform differentiation, and proprietary assets.
The company’s business model is built around proprietary technology platforms and a portfolio of clinical-stage drug candidates. Its lead asset is TG4050, an individualized therapeutic vaccine derived from the myvac® platform. TG4050 is designed for each patient based on tumor mutations identified through sequencing, and it leverages AI-enabled neoantigen prediction technology through a strategic collaboration with NEC Bio. Transgene is also advancing BT-001, an armed oncolytic virus aimed at solid tumors, as well as additional programs from its Invir.IO® platform. This positions the company in highly specialized segments of immuno-oncology, where scientific differentiation, intellectual property, and clinical readouts are critical.
Read moreShow less
From a market perspective, Transgene remains a small-cap biotech focused on clinical assets rather than commercial products. Its investment case is primarily driven by development milestones, clinical data, and strategic partnerships. Recent company communications highlight encouraging clinical results for TG4050 and BT-001, alongside extended financial visibility supported by its reference shareholder Institut Mérieux/TSGH and equity financing transactions. As of late 2025, the company stated that its cash resources and committed support gave it funding runway through the end of December 2026.
Transgene is mainly rooted in France, with its headquarters and historic operations in Strasbourg, while maintaining collaborations with a broad international network of academic and industrial partners. Its recent disclosures show sustained clinical momentum, especially around TG4050, which is currently the main medium-term value driver. Overall, Transgene combines niche scientific expertise, a differentiated technology base, and the high-risk/high-reward profile typical of listed biotech companies.
